The Sai Parenterals IPO finally hit the stock market on April 2. The debut wasn’t dramatic. It wasn’t weak either. It was somewhere in between — a quiet, steady entry that reflects the overall mood around the issue.
Let’s break it down in a simple, clear way.
Market Performance: Sai Parenterals IPO Listing Day
The Sai Parenterals IPO listing saw a modest premium on both major exchanges.
- BSE Listing Price: ₹405
→ Up 3.32% from IPO price of ₹392 - NSE Listing Price: ₹400
→ Up 2.04% from IPO price
The stock opened slightly higher, but the gains remained limited. There was no sharp spike. No aggressive selling either. Just a calm start.
This kind of listing usually signals one thing — balanced sentiment.
Main News: A Quiet Debut After a Moderate IPO Response
The Sai Parenterals IPO didn’t see overwhelming demand during its subscription window. That tone carried into listing day.
The IPO was subscribed 1.08 times overall. That’s just about fully booked — nothing more.
Here’s how different investor categories responded:
- QIB (Institutional Investors): 1.73x
- NII (High Net-Worth Individuals): 2.45x
- Retail Investors: Only 12% subscribed
The weak retail participation clearly shows that small investors stayed cautious.
And that caution showed up on listing day too.
Sai Parenterals IPO Details You Should Know
The Sai Parenterals IPO was a ₹409 crore issue. It combined fresh fundraising with partial stake sale.
Breakdown of the IPO
- Total Issue Size: ₹409 crore
- Fresh Issue: ₹285 crore
- Offer for Sale (OFS): ₹123.79 crore
IPO Pricing
- Price Band: ₹372 – ₹392 per share
- Final Issue Price: ₹392
- Lot Size: 38 shares
IPO Timeline
- Opening Date: March 24
- Closing Date: March 27
The structure was straightforward. No complex layers. Just a standard mix of fresh capital and promoter exit.
Where the IPO Money Will Be Used?
The company has clearly defined where the funds from the Sai Parenterals IPO will go.
Utilisation of Funds
- ₹111 crore → Capacity expansion & manufacturing upgrade
- ₹18 crore → New R&D centre setup
- ₹14.30 crore → Debt repayment
- Remaining → General corporate purposes
This shows a mix of growth and balance sheet strengthening.
Company Details: What Sai Parenterals Actually Does?
Sai Parenterals operates in the pharmaceutical space. But it’s not just a plain vanilla drug maker.
The company works across multiple areas:
- Branded generic formulations
- Research and development
- Manufacturing capabilities
- CDMO services (Contract development and manufacturing)
It caters to both:
- Domestic markets
- International markets
That diversification helps reduce dependency on a single revenue stream.
IPO Allocation Structure
The Sai Parenterals IPO followed the usual allocation pattern:
- Up to 50% reserved for QIBs
- Up to 15% for NIIs
- Up to 35% for retail investors
Despite this allocation, retail participation remained low — a key highlight of this IPO.
Key Players Behind the IPO
- Lead Manager: Arihant Capital Markets Ltd.
- Registrar: Bigshare Services Pvt. Ltd.
These are the entities that handled the IPO process end-to-end.
Summary: Sai Parenterals IPO in One View
The Sai Parenterals IPO listing tells a simple story.
- The stock listed with small gains of 2–3%
- Subscription levels were just above full
- Retail investors showed limited interest
- Listing day reflected neutral market sentiment
There was no hype. No panic. Just a measured response.
And sometimes, that says more than a big listing pop.
